首页> 外文期刊>Kidney International Reports >The Longitudinal Study of Liver Cysts in?Patients With Autosomal Dominant Polycystic Kidney Disease and Polycystic Liver Disease
【24h】

The Longitudinal Study of Liver Cysts in?Patients With Autosomal Dominant Polycystic Kidney Disease and Polycystic Liver Disease

机译:常染色体显性多囊肾和多囊肝病患者肝囊肿的纵向研究

获取原文
           

摘要

Introduction Although polycystic liver disease (PCLD) is one of the extrarenal complications in patients with autosomal dominant polycystic kidney disease (ADPKD), longitudinal changes and the association with total liver volume (TLV) have not been clearly elucidated yet. Methods Patients with ADPKD were chosen who underwent computed tomography or magnetic resonance imaging twice or more during August 2003 through December 2015. TLV, each cyst volume, and the proportion of parenchyma were measured. The natural history of liver cysts and the association between TLV and liver cysts were evaluated. To compare with liver cysts in ADPKD patients with PCLD, simple liver cysts in patients without ADPKD were also evaluated. Results TLV at baseline and its growth rate in all the patients with ADPKD, whose serum creatinine, estimated glomerular filtration rate, and total kidney volume were 1.45 mg/dl (0.76–2.32 mg/dl), 38.5 ml/min per 1.73 m 2 (18.7–57.9 ml/min per 1.73 m 2 ), and 1394 ml (773–2861 ml), were 1431 ml (1062–1749 ml) and??0.95%/yr (?3.16 to 4.94%/yr), respectively, in the observation period (median, 1063 days). Neither TLV nor its growth rate was significantly different between ADPKD patients with PCLD and those without PCLD. The growth rate of 79 liver cysts was 39.5%/yr (17.5–80.8%/yr) in PCLD patients with ADPKD. It was significantly larger than that of 60 simple liver cysts in the non-ADPKD group, 11.0%/yr (?2.2 to 33.1%/yr). Moreover, the proportion of parenchyma reduced, whereas that of total cyst volume increased significantly ( P ?= 0.001). Discussion The reduction of parenchyma was accompanied by the growth of liver cysts during time course in PCLD patients with ADPKD.
机译:简介尽管多囊性肝病(PCLD)是常染色体显性遗传性多囊性肾病(ADPKD)患者的肾外并发症之一,但纵向变化以及与总肝体积(TLV)的关系尚未明确阐明。方法选择2003年8月至2015年12月两次或两次以上的计算机体层摄影或磁共振成像检查的ADPKD患者。测量TLV,每个囊肿的体积和实质的比例。评估肝囊肿的自然病史以及TLV和肝囊肿之间的关联。为了与患有PCLD的ADPKD患者的肝囊肿进行比较,还对未患有ADPKD的患者的简单肝囊肿进行了评估。结果所有ADPKD患者的基线时TLV及其增长率,其血清肌酐,估计的肾小球滤过率和总肾脏体积分别为1.45 mg / dl(0.76-2.32 mg / dl),38.5 ml / min / 1.73 m 2 (每1.73 m 2分别为18.7-57.9 ml / min)和1394 ml(773-2861 ml),分别为1431 ml(1062-1749 ml)和0.95%/年(?3.16至4.94%/年)。 ,在观察期内(中位数1063天)。患有PCLD的ADPKD患者与未患有PCLD的ADPKD患者之间,TLV或其增长率均无显着差异。 PCLD合并ADPKD患者的79个肝囊肿的增长率为39.5%/年(17.5–80.8%/年)。与非ADPKD组的60个单纯肝囊肿相比,它显着更大,为11.0%/年(?2.2至33.1%/年)。而且,薄壁组织的比例减少,而囊肿总体积的比例显着增加(P≤0.001)。讨论在PCLD合并ADPKD的患者中,随着时间的推移,实质的减少伴随着肝囊肿的生长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号